Teladoc Health reports news on its virtual care business, including financial results, segment performance, product innovation, technology investment, and governance updates. The company delivers and orchestrates care across patients, care providers, platforms, and partners through relationships with health plans, employers, providers, health systems, and consumers.
Recurring updates focus on Integrated Care, which includes virtual care solutions such as primary care, mental health, chronic care management, and telehealth enablement, and BetterHelp, the company’s direct-to-consumer online mental health offering. Company news also includes earnings calls, investor conference participation, board appointments and retirements, inducement equity awards, and strategic commentary on its clinical model and care-delivery platform.
Teladoc Health (NYSE: TDOC) will release its third quarter 2026 financial results on October 28, 2026, after the market closes. The company will host a conference call to review the results at 5:00 p.m. ET that day. A live audio webcast will be available, with a replay accessible shortly after the call for approximately 90 days.
Teladoc Health (TDOC) announced two AI-powered capabilities within its Solo platform for hospitals and health systems: SoloVitals and SoloScribe.
SoloVitals measures heart rate and respiration rate without physical contact, using a patient’s camera-equipped device to analyze subtle facial skin color changes. SoloScribe creates structured clinical notes during virtual visits and transfers a templated summary into the electronic health record. Both capabilities are embedded within Solo. SoloScribe is generally available; SoloVitals is available to select customers in private preview, with Teladoc Health expecting full general release in December 2026.
Teladoc Health (TDOC) named Jonathan Dorfman its next chief legal officer and secretary, effective November 2, 2026.
Current chief legal officer and secretary Adam Vandervoort has decided to resign effective November 1, after 11 years with the company. Dorfman is currently senior vice president of securities and corporate law. He joined Teladoc Health in 2020 through its acquisition of Livongo, where he led SEC compliance and corporate governance. His most recent responsibilities at Teladoc Health include SEC reporting and disclosure, corporate governance, capital markets, and mergers and acquisitions.
Teladoc Health (TDOC) has granted equity inducement awards to its new Chief Financial Officer, effective September 1, 2026.
Michael Grasher received restricted stock units covering 239,616 shares of common stock and performance stock units (PSUs) with a 239,616-share target, with up to 479,232 shares potentially earned. Time-based RSUs vest 50% on the first anniversary of grant and the remainder in six equal quarterly installments starting 15 months after grant. PSUs are tied to 2026 adjusted EBITDA and 2026–2028 compound annual revenue growth, with earned EBITDA PSUs vesting on a similar staged schedule and Revenue CAGR PSUs vesting on March 1, 2029. Awards were approved under the 2023 Employment Inducement Incentive Award Plan pursuant to NYSE Rule 303A.08.
Teladoc Health (NYSE: TDOC) has appointed Michael Grasher as Chief Financial Officer, effective immediately. Grasher brings more than three decades of experience in insurance and financial services, including over 12 years in CFO roles at public and private companies.
He most recently served as CFO of IFG Companies and previously held CFO and Executive Vice President positions at Fortegra and AMERISAFE. Earlier in his career, he spent over a decade in equity research, including as a Managing Director at Piper Jaffray. According to Teladoc Health, his background in financial stewardship, operational discipline and strategy is expected to support the company’s focus on disciplined, sustainable growth.
Teladoc Health (NYSE: TDOC) has appointed financial executive Mark V. Anquillare, former president and chief operating officer of Verisk Analytics, to its board of directors, effective August 3, 2026. He will serve on the board’s Audit and Compensation committees.
According to Teladoc Health, Anquillare brings over 30 years of financial and executive leadership, including roles as Verisk’s chief financial officer and chief operating officer, where he led its 2009 IPO and oversaw insurance and government-facing businesses. He currently serves on the boards of Guidewire Software, RegEd and Bamboo Insurance and previously served on TruBridge’s board. He holds an MBA from Rutgers Business School and a BBA from the University of Notre Dame.
Teladoc Health (NYSE: TDOC) reported Second Quarter 2026 revenue of $606.9 million, down 4% year-over-year, with a net loss of $38.9 million ($0.21 per share) and adjusted EBITDA of $65.7 million, down 5%.
Integrated Care revenue rose 1% to $394.3 million with a 16.5% adjusted EBITDA margin, while BetterHelp revenue fell 12% to $212.6 million with a 0.2% margin. U.S. revenue declined 6% and international revenue grew 7%. Chronic care program enrollment increased 14% to 1.272 million, and BetterHelp paying users declined 11%.
For full-year 2026, Teladoc Health expects revenue of $2.36–$2.45 billion, adjusted EBITDA of $271–$303 million, free cash flow of $130–$170 million, Integrated Care revenue growth of 0.8–2.4%, and BetterHelp revenue decline of 19.0–12.7%.
Teladoc Health (NYSE: TDOC) will release its second quarter 2026 financial results on Wednesday, July 29, 2026, after the market close. The company will host a conference call to review the results at 5:00 p.m. ET the same day.
U.S. participants can join by dialing 833-461-5787 with meeting ID 478 236 923, while international participants can obtain local numbers via a dedicated link. A live audio webcast and an on-demand replay (available for about 90 days) will be accessible through Teladoc Health's investor relations events webpage.
Teladoc Health (NYSE: TDOC) granted an employment inducement award to new BetterHelp Head of Product, David Packles. Effective July 1, 2026, he received 50,000 restricted stock units of common stock.
The RSUs vest one-third after one year, then quarterly over two additional years, under the 2023 Employment Inducement Incentive Award Plan pursuant to NYSE Rule 303A.08.
SenesTech (NASDAQ: SNES) appointed veteran sales executive Jack Karabees as Executive Vice President of Sales. He will lead the sales organization, focusing on revenue growth, broader market penetration and stronger customer relationships.
Karabees has decades of B2B sales leadership and has already consulted for SenesTech on commercial strategy.